Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AC Immune SA ACIU

Healthcare Biotechnology
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small... see more

Recent & Breaking News (NDAQ:ACIU)

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease

GlobeNewswire 7 days ago

AC Immune to Present at the Jefferies 2024 London Healthcare Conference

GlobeNewswire 8 days ago

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

GlobeNewswire November 5, 2024

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease

GlobeNewswire September 17, 2024

AC Immune's PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions

GlobeNewswire August 28, 2024

AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

GlobeNewswire August 6, 2024

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

GlobeNewswire July 31, 2024

AC Immune's ACI-35.030 (now "JNJ-2056") Granted FDA Fast Track Designation for Alzheimer's Disease

GlobeNewswire July 25, 2024

AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024

GlobeNewswire July 16, 2024

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024

GlobeNewswire May 28, 2024

AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update

GlobeNewswire May 13, 2024

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease

GlobeNewswire May 13, 2024

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

GlobeNewswire March 14, 2024

AC Immune Announces Upcoming Presentations at AD/PD(TM) 2024

GlobeNewswire February 22, 2024

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

GlobeNewswire January 22, 2024

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases

GlobeNewswire January 3, 2024

AC Immune Announces Pricing of Underwritten Offering of Common Shares

GlobeNewswire December 15, 2023

AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial

GlobeNewswire December 15, 2023

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

GlobeNewswire December 1, 2023

AC Immune to Present at the Jefferies 2023 London Healthcare Conference

GlobeNewswire November 7, 2023